You can buy or sell Compugen and other stocks, options, ETFs, and crypto commission-free!
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. Read More The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.
Holon, Tel Aviv
52 Week High
52 Week Low
Research And Development
PR NewswireMar 12
Compugen Announces Issuance of Two U.S. Composition of Matter Patents for COM701, Its Lead Immuno-Oncology Product Candidate
HOLON, Israel, March 12, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that the United States Patent and Trademark Office (USPTO) has granted two composition of matter patents for COM701, the Company's lead immuno-oncology therapeutic antibody candidate. One patent covers the composition of COM701 and backup antibodies, while the second patent covers the composition of any antibody having the fragme...
Seeking AlphaMar 12
Compugen nabs two new patents in U.S. for COM701; shares up 4% premarket
The USPTO has granted two composition of matter patents for Compugen's (NASDAQ:CGEN) COM701, lead immuno-oncology therapeutic antibody candidate.
Expected May 8, Pre-Market